AFFILIATIONS
1 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
2 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
3 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
4 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
5 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
6 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
7 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
8 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
9 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
10 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
11 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China, Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
ABSTRACT
Introduction: Peripheral neuropathy (PN) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains poorly characterized, with heterogeneous manifestations and overlapping etiologies that complicate timely recognition and management. We aim to describe the clinical and electrophysiological features, risk factors, treatment response, and outcomes of peripheral neuropathy following allo-HSCT
Methods: We conducted a retrospective chart review and a 1:3-matched nested case-control study of adult allo-HSCT recipients at the Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine between 2021 and 2025. Each PN case was matched 1:3 to controls by sex, age at transplantation, and transplantation date. The date of the first abnormal nerve conduction study (NCS) was defined as the index date, on which all matched controls were alive and PN-free.
Results: Of the 1895 patients who underwent allo-HSCT, 40 patients (2.1%) had PN. The median time from transplantation to PN onset was 147.5 days (range, 19- 657 days). 26 patients (65.0%) were unable to walk independently and required a wheelchair at diagnosis. Acute polyradiculoneuropathy (Guillain–Barré syndrome, GBS) was diagnosed in 27 patients (67.5%), of whom 11 (40.7%) showed an acute motor axonal neuropathy (AMAN) pattern. NCS showed sensorimotor involvement in 20/40 patients and motor-only involvement in 17/40. The neuropathy was predominantly axonal (27/40), usually with a generalized symmetric distribution (27/40). Reduced distal CMAP amplitude was the main motor abnormality (47.4%–73.6%), particularly in the median, ulnar, and peroneal nerves. Three months after treatment, 31 of 38 evaluable patients (81.6%) had at least partial recovery of motor and/or sensory function, including 6 (15.8%) without residual deficits, although 17 (44.7%) remained unable to walk independently and required a wheelchair. Within 30 days before the index date, fungal infection was observed in 11/40 patients with PN and 3/120 controls. CMV infection within 30 days before the index date (aOR, 5.85; 95% CI, 1.64–20.84; P = 0.006) and grade III–IV acute graft-versus-host disease (aGVHD) (aOR, 3.89; 95% CI, 1.04–14.55; P = 0.043) were identified as independent risk factors for PN after allo-HSCT. Patients with PN had worse overall survival (P = 0 .039) and progression-free survival (P = 0.008), with higher cumulative incidences of nonrelapse mortality (P = 0.034) and relapse (P = 0 .048), than those without PN.
Conclusions: These findings provide a detailed clinical and electrophysiological profile of PN after allo-HSCT and may facilitate its recognition and diagnostic evaluation. PN is rare after allo-HSCT but often severe. It predominantly involves motor axons and most often presents as GBS, with AMAN as a prominent subtype. CMV infection and grade III–IV aGVHD were independently associated with PN. New-onset limb weakness or numbness should prompt timely neurological assessment and NCS, particularly in high-risk recipients. Given its association with adverse transplant outcomes, patients with PN warrant close follow-up.